Stem cell treatment for blood cell changes
Part of Blood & lymphatic clinical trials.
This trial tests whether a medication can improve blood cell counts and reduce the risk of serious blood diseases in people with low blood counts and a specific genetic mutation. It aims to keep early changes from turning into leukemia or other blood cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 85 years old.
- You have low blood cell counts (anemia, low platelets, or low white blood cells) for at least 4 months.
- You have a specific genetic change in your blood cells, known as a clonal hematopoiesis mutation, with a variant allele fraction of at least 10%.
- If you have HIV, you must be on effective treatment with a low viral load.
- You are generally active and able to care for yourself (ECOG 0 or 1).
- You do not have serious heart, liver, kidney, or active infection problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a condition called clonal hematopoiesis (CH), where some blood cells have changes that may affect their health. It aims to prevent, treat, and better understand CH. You may qualify if you are 55 or older and have low blood counts that persist over time.
This trial tests a drug called enasidenib for people who have had low blood counts for at least 6 months and have a specific mutation in the IDH2 gene. The study aims to see if the drug can improve blood counts and is done mostly from home with fewer clinic visits.
This trial tests a drug called luspatercept for people with a condition called CCUS, where they have low blood counts and a gene change. The goal is to see if the drug can improve blood counts and reduce symptoms like fatigue or bleeding risk.
This trial tests an early treatment for people with a condition called high-risk CCUS, where low blood counts and gene changes raise the risk of developing blood cancer. The goal is to see if intervening early can prevent or delay progression to leukemia or MDS.
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
Hear when a new Clonal Hematopoiesis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.